Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended
Jan. 31, 2015	Jan. 31, 2014	Jan. 31, 2015	Jan. 31, 2014
Revenues:
Clinical laboratory services	$ 14,725us-gaap_SalesRevenueServicesNet	$ 13,848us-gaap_SalesRevenueServicesNet	$ 30,547us-gaap_SalesRevenueServicesNet	$ 28,707us-gaap_SalesRevenueServicesNet
Product revenues	7,723us-gaap_SalesRevenueGoodsNet	8,054us-gaap_SalesRevenueGoodsNet	15,725us-gaap_SalesRevenueGoodsNet	15,717us-gaap_SalesRevenueGoodsNet
Royalty and license fee income	644enz_RoyaltyAndLicenseFeeIncome	1,026enz_RoyaltyAndLicenseFeeIncome	1,644enz_RoyaltyAndLicenseFeeIncome	2,637enz_RoyaltyAndLicenseFeeIncome
Total revenues	23,092us-gaap_SalesRevenueNet	22,928us-gaap_SalesRevenueNet	47,916us-gaap_SalesRevenueNet	47,061us-gaap_SalesRevenueNet
Operating expenses:
Cost of clinical laboratory services	9,246us-gaap_CostOfServices	9,292us-gaap_CostOfServices	19,376us-gaap_CostOfServices	19,001us-gaap_CostOfServices
Cost of product revenues	3,818us-gaap_CostOfGoodsSold	3,865us-gaap_CostOfGoodsSold	7,513us-gaap_CostOfGoodsSold	7,712us-gaap_CostOfGoodsSold
Research and development	834us-gaap_ResearchAndDevelopmentExpense	832us-gaap_ResearchAndDevelopmentExpense	1,625us-gaap_ResearchAndDevelopmentExpense	1,649us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601us-gaap_ProvisionForDoubtfulAccounts	912us-gaap_ProvisionForDoubtfulAccounts	1,142us-gaap_ProvisionForDoubtfulAccounts	1,784us-gaap_ProvisionForDoubtfulAccounts
Legal fee expense	2,804us-gaap_LegalFees	1,496us-gaap_LegalFees	5,270us-gaap_LegalFees	2,877us-gaap_LegalFees
Operating income (loss)	(3,881)us-gaap_OperatingIncomeLoss	(3,553)us-gaap_OperatingIncomeLoss	(6,965)us-gaap_OperatingIncomeLoss	(6,574)us-gaap_OperatingIncomeLoss
Other income (expense)
Other	(17)us-gaap_OtherNonoperatingIncomeExpense	15us-gaap_OtherNonoperatingIncomeExpense	2us-gaap_OtherNonoperatingIncomeExpense	76us-gaap_OtherNonoperatingIncomeExpense
Foreign exchange gain (loss)	(259)	20	(731)	317
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Cost of Clinical Laboratory Services [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Cost of Clinical Laboratory Services [Member]
Share-based compensation included in above:
Share-based compensation	2	2	3	4
Research and Development Expense [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation	1		2	1
Selling, General and Administrative Expenses [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	12	9	21	19
Selling, General and Administrative Expenses [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	3	5	3	9
Selling, General and Administrative Expenses [Member] \| Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Selling, General and Administrative Expenses [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation	102	107	198	207
Total [Member] \| Clinical Labs [Member]
Share-based compensation included in above:
Share-based compensation	14	11	24	23
Total [Member] \| Life Sciences [Member]
Share-based compensation included in above:
Share-based compensation	4	5	5	10
Total [Member] \| Other Segments [Member]
Share-based compensation included in above:
Share-based compensation	87	93	174	179
Total [Member] \| Consolidated [Member]
Share-based compensation included in above:
Share-based compensation	105	109	203	212
Clinical Labs [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Total revenues	14,725	13,848	30,547	28,707
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Research and development		3		14
Selling, general and administrative	5,089	4,981	10,157	10,031
Provision for uncollectible accounts receivable	658	920	1,189	1,764
Legal fee expense	41	142	131	290
Total operating expenses	15,034	15,338	30,853	31,100
Operating income (loss)	(309)	(1,490)	(306)	(2,393)
Other income (expense)
Interest	(12)	(11)	(39)	(22)
Other	4	9	6	27
Income (loss) before income taxes	(317)	(1,492)	(339)	(2,388)
Depreciation and amortization included above	357	355	714	710
Share-based compensation included in above:
Capital expenditures	338	103	589	362
Life Sciences [Member]
Revenues:
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	8,367	9,080	17,369	18,354
Operating expenses:
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	635	543	1,183	1,069
Selling, general and administrative	2,704	3,318	5,853	6,813
Provision for uncollectible accounts receivable	(57)	(8)	(47)	20
Legal fee expense	(53)	15	(51)	37
Total operating expenses	7,047	7,733	14,451	15,651
Operating income (loss)	1,320	1,347	2,918	2,703
Other income (expense)
Interest	5	3	7	8
Other	(29)	(6)	(35)	21
Foreign exchange gain (loss)	(259)	20	(731)	317
Income (loss) before income taxes	1,037	1,364	2,159	3,049
Depreciation and amortization included above	555	621	1,113	1,262
Share-based compensation included in above:
Capital expenditures	51	7	64	82
Therapeutics [Member]
Operating expenses:
Research and development	199	286	442	566
Total operating expenses	199	286	442	566
Operating income (loss)	(199)	(286)	(442)	(566)
Other income (expense)
Income (loss) before income taxes	(199)	(286)	(442)	(566)
Depreciation and amortization included above	1	2	2	6
Other Segments [Member]
Operating expenses:
Selling, general and administrative	1,877	1,785	3,945	3,768
Legal fee expense	2,816	1,339	5,190	2,550
Total operating expenses	4,693	3,124	9,135	6,318
Operating income (loss)	(4,693)	(3,124)	(9,135)	(6,318)
Other income (expense)
Interest	(42)	(44)	(86)	(100)
Other	8	12	31	28
Income (loss) before income taxes	(4,727)	(3,156)	(9,190)	(6,390)
Depreciation and amortization included above	22	24	44	49
Consolidated [Member]
Revenues:
Clinical laboratory services	14,725	13,848	30,547	28,707
Product revenues	7,723	8,054	15,725	15,717
Royalty and license fee income	644	1,026	1,644	2,637
Total revenues	23,092	22,928	47,916	47,061
Operating expenses:
Cost of clinical laboratory services	9,246	9,292	19,376	19,001
Cost of product revenues	3,818	3,865	7,513	7,712
Research and development	834	832	1,625	1,649
Selling, general and administrative	9,670	10,084	19,955	20,612
Provision for uncollectible accounts receivable	601	912	1,142	1,784
Legal fee expense	2,804	1,496	5,270	2,877
Total operating expenses	26,973	26,481	54,881	53,635
Operating income (loss)	(3,881)	(3,553)	(6,965)	(6,574)
Other income (expense)
Interest	(49)	(52)	(118)	(114)
Other	(17)	15	2	76
Foreign exchange gain (loss)	(259)	20	(731)	317
Income (loss) before income taxes	(4,206)	(3,570)	(7,812)	(6,295)
Depreciation and amortization included above	935	1,002	1,873	2,027
Share-based compensation included in above:
Capital expenditures	$ 389	$ 110	$ 653	$ 444

Name:	enz_OperatingExpensesAbstract0
Namespace Prefix:	enz_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Name:	enz_OtherIncomeExpenseAbstract0
Namespace Prefix:	enz_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	enz_RevenuesAbstract0
Namespace Prefix:	enz_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Also the revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.

+ References

No definition available.

+ Details

Name:	enz_RoyaltyAndLicenseFeeIncome
Namespace Prefix:	enz_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	enz_ShareBasedCompensationIncludedInAboveAbstract
Namespace Prefix:	enz_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_CostOfGoodsSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_CostOfServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total costs of sales and operating expenses for the period.

+ References

+ Details

Name:	us-gaap_CostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

+ Details

Name:	us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name:	us-gaap_ForeignCurrencyTransactionGainLossBeforeTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name:	us-gaap_InterestExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

+ Details

Name:	us-gaap_LegalFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name:	us-gaap_PaymentsForProceedsFromProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name:	us-gaap_ProvisionForDoubtfulAccounts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

+ Details

Name:	us-gaap_SalesRevenueServicesNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=enz_CostOfClinicalLaboratoryServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=enz_TotalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=enz_ClinicalLabsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=enz_ConsolidatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=enz_LifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=enz_TherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: